The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.
Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
In Nature this week: study of gene drive feasibility in lab mice, circulating tumor DNA from cerebrospinal fluid to track glioma progression, and more.
The firm's has expanded its ctDNA sequencing test to cover 17 genes, enough to provide a readout of microsatellite instability for guiding cancer immunotherapy use.
The firm's new RT-PCR assay identifies 20 gene fusion between NTRK1/2/3 and other genes, allowing clinicians to potentially detect rare forms of different cancers.
The firm is moving into a larger facility after its first full year of profitability and planning new hires to support its plans to bring liquid biopsy kits through the FDA.
Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
